The document provides information on several COVID-19 vaccines, including Pfizer, Moderna, Johnson & Johnson, Covaxin, Covishield, Sputnik V, and vaccines from China. It describes the manufacturers, countries of origin, vaccine types, dosing schedules, effectiveness and clinical trial demographics for each vaccine. Overall, the vaccines were shown to effectively prevent COVID-19 illness and reduce severe outcomes, with effectiveness rates ranging from 66.3% to 97% depending on the specific vaccine.
In this presentation, we discuss the clinical trial process for the new Covid-19 vaccines. We discuss the different vaccine types. We also discuss the Covid-19 vaccines that the UK is currently using in the NHS, as well as vaccines likely to be used in the next year.
This document provides an overview of COVID-19. It discusses that coronaviruses are a family of viruses that infect humans and other mammals. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. The virus enters cells via the ACE2 receptor and causes respiratory illness. While most cases are mild, approximately 20% develop severe symptoms requiring hospitalization. The virus can spread before and during symptoms. Gastrointestinal symptoms like diarrhea may also occur. Those at highest risk include older adults and those with pre-existing medical conditions.
This document provides information about Coronavirus Disease 2019 (COVID-19). It discusses the epidemiology, causes, signs and symptoms, diagnosis, management, and preventive measures of COVID-19. The objectives are to introduce COVID-19, discuss its transmission, clinical presentation, testing and treatment approaches, complications, and prevention. Key points covered include that COVID-19 is caused by a novel coronavirus, spreads through respiratory droplets, and can cause pneumonia, respiratory failure, and multi-organ dysfunction in severe cases. Diagnosis is via PCR testing of respiratory samples and management focuses on supportive care. Prevention emphasizes hand hygiene, surface disinfection, and use of personal protective equipment during patient care activities.
Features, Evaluation and Treatment Coronavirus (COVID-19)
The WHO and other organizations have issued the following general recommendations:
Avoid close contact with subjects suffering from acute respiratory infections.
Wash your hands frequently, especially after contact with infected people or their environment.
Avoid unprotected contact with farm or wild animals.
People with symptoms of acute airway infection should keep their distance, cover coughs or sneezes with disposable tissues or clothes and wash their hands.
Strengthen, in particular, in emergency medicine departments, the application of strict hygiene measures for the prevention and control of infections.
Individuals that are immunocompromised should avoid public gatherings.
Patients and families should receive instruction to:
Avoid close contact with subjects suffering from acute respiratory infections.
Wash their hands frequently, especially after contact with sick people or their environment.
Avoid unprotected contact with farm or wild animals.
People with symptoms of acute airway infection should keep their distance, cover coughs or sneezes with disposable tissues or clothes and wash their hands.
Immunocompromised patients should avoid public exposure and public gatherings. If an immunocompromised individual must be in a closed space with multiple individuals present, such as a meeting in a small room; masks, gloves, and personal hygiene with antiseptic soap should be undertaken by those in close contact with the individual. In addition, prior room cleaning with antiseptic agents should be undertaken and performed before exposure. However, considering the danger involved to these individuals, exposure should be avoided unless a meeting, group event, etc. is a true emergency.
Strict personal hygiene measures are necessary for the prevention and control of this infection.
The document provides an overview of the COVID-19 pandemic including:
- Coronaviruses and COVID-19 virus virology
- Modes of transmission are through respiratory droplets and contacting contaminated surfaces
- Clinical features are fever, cough and fatigue with risk of severe disease higher in older people and those with underlying conditions
- Diagnosis is through viral testing like PCR from respiratory samples and antibody tests
- Treatment focuses on supportive care while vaccines are still in development
A brief overview of the process of vaccine production, clinical trials, and licensing, along with a summary of the different vaccines platforms and vaccine candidates.
In this presentation, we discuss the clinical trial process for the new Covid-19 vaccines. We discuss the different vaccine types. We also discuss the Covid-19 vaccines that the UK is currently using in the NHS, as well as vaccines likely to be used in the next year.
This document provides an overview of COVID-19. It discusses that coronaviruses are a family of viruses that infect humans and other mammals. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. The virus enters cells via the ACE2 receptor and causes respiratory illness. While most cases are mild, approximately 20% develop severe symptoms requiring hospitalization. The virus can spread before and during symptoms. Gastrointestinal symptoms like diarrhea may also occur. Those at highest risk include older adults and those with pre-existing medical conditions.
This document provides information about Coronavirus Disease 2019 (COVID-19). It discusses the epidemiology, causes, signs and symptoms, diagnosis, management, and preventive measures of COVID-19. The objectives are to introduce COVID-19, discuss its transmission, clinical presentation, testing and treatment approaches, complications, and prevention. Key points covered include that COVID-19 is caused by a novel coronavirus, spreads through respiratory droplets, and can cause pneumonia, respiratory failure, and multi-organ dysfunction in severe cases. Diagnosis is via PCR testing of respiratory samples and management focuses on supportive care. Prevention emphasizes hand hygiene, surface disinfection, and use of personal protective equipment during patient care activities.
Features, Evaluation and Treatment Coronavirus (COVID-19)
The WHO and other organizations have issued the following general recommendations:
Avoid close contact with subjects suffering from acute respiratory infections.
Wash your hands frequently, especially after contact with infected people or their environment.
Avoid unprotected contact with farm or wild animals.
People with symptoms of acute airway infection should keep their distance, cover coughs or sneezes with disposable tissues or clothes and wash their hands.
Strengthen, in particular, in emergency medicine departments, the application of strict hygiene measures for the prevention and control of infections.
Individuals that are immunocompromised should avoid public gatherings.
Patients and families should receive instruction to:
Avoid close contact with subjects suffering from acute respiratory infections.
Wash their hands frequently, especially after contact with sick people or their environment.
Avoid unprotected contact with farm or wild animals.
People with symptoms of acute airway infection should keep their distance, cover coughs or sneezes with disposable tissues or clothes and wash their hands.
Immunocompromised patients should avoid public exposure and public gatherings. If an immunocompromised individual must be in a closed space with multiple individuals present, such as a meeting in a small room; masks, gloves, and personal hygiene with antiseptic soap should be undertaken by those in close contact with the individual. In addition, prior room cleaning with antiseptic agents should be undertaken and performed before exposure. However, considering the danger involved to these individuals, exposure should be avoided unless a meeting, group event, etc. is a true emergency.
Strict personal hygiene measures are necessary for the prevention and control of this infection.
The document provides an overview of the COVID-19 pandemic including:
- Coronaviruses and COVID-19 virus virology
- Modes of transmission are through respiratory droplets and contacting contaminated surfaces
- Clinical features are fever, cough and fatigue with risk of severe disease higher in older people and those with underlying conditions
- Diagnosis is through viral testing like PCR from respiratory samples and antibody tests
- Treatment focuses on supportive care while vaccines are still in development
A brief overview of the process of vaccine production, clinical trials, and licensing, along with a summary of the different vaccines platforms and vaccine candidates.
Coronaviruses are a group of related viruses that cause diseases in mammals and birds. In humans, coronaviruses cause respiratory tract infections that can be mild, such as some cases of the common cold, and others that can be lethal, such as SARS, MERS, and COVID-19. Symptoms in other species vary: in chickens, they cause an upper respiratory tract disease, while in cows and pigs they cause diarrhea. There are yet to be vaccines or antiviral drugs to prevent or treat human coronavirus infections.
detailed information about COVID_19 and Corona Viruses how it would be transmitted and all the preventive measures
information about the vaccine of corona virus
This document summarizes information about different COVID-19 vaccines. It discusses the mechanism of action, efficacy, dosing schedule, storage requirements, and common side effects of several major vaccines, including Covishield, Covaxin, Pfizer/BioNTech, Moderna, Sinovac, Sinopharm, Johnson & Johnson, Sputnik V and Novavax. The document also briefly outlines different vaccine production approaches such as viral vector vaccines, mRNA vaccines, inactivated virus vaccines, and virus-like particle vaccines.
Webinar Series on COVID-19 vaccine: Jointly organized by Malaysian Society of Infection Control and Infectious Diseases (MyICID) & Institute for Clinical Research (ICR), NIH
Speaker: Dr.Benedict Sim Lim Heng is a Consultant Infectious Disease Physician at the Sungai Buloh Hospital, Ministry of Health Malaysia.
The document provides information about Coronavirus (COVID-19). It describes how COVID-19 is caused by SARS-CoV-2 virus and spreads mainly through respiratory droplets from infected individuals. Common symptoms include fever, cough and shortness of breath. While most cases are mild, it can progress to pneumonia and multi-organ failure in some cases. The mortality rate is around 2%. Currently there is no vaccine, though some antiviral medications are being tested. Prevention relies on hand washing and hygiene measures.
Zika virus is spread by daytime-active Aedes mosquitoes and often causes mild or no symptoms. It was isolated in Uganda in 1947 and has recently spread to areas in the Americas. The virus is associated with microcephaly in fetuses when the mother is infected during pregnancy and Guillain-Barré syndrome in adults. While medications and vaccines are currently unavailable, health organizations recommend precautions for pregnant women such as postponing travel to affected areas.
The document discusses adult immunization strategies in India. It notes there is a lack of consensus on optimal adult immunization strategies in developing countries like India due to a lack of reliable epidemiological data, efficacy and safety data of vaccination strategies, and data on monitoring immunization adequacy. The document provides guidance on recommended vaccines for different adult groups and schedules for vaccines including tetanus, diphtheria, pertussis, hepatitis A, hepatitis B, HPV, influenza, measles, mumps, rubella, varicella, herpes zoster and pneumococcal vaccines.
Chikungunya is a viral disease transmitted by infected mosquitoes that causes fever and severe joint pain. It is caused by the chikungunya virus which is spread between humans by Aedes albopictus and Aedes aegypti mosquitoes. Large outbreaks have occurred in parts of Africa, India, and Southeast Asia. Currently, there is no vaccine available and treatment focuses on relieving symptoms.
COVID-19 (coronavirus disease 2019) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019 novel coronavirus (2019-nCoV), a strain of coronavirus. The first cases were seen in Wuhan, China in December 2019 before spreading globally. The current outbreak was recognized as a pandemic on 11 March 2020.
The non-specific imaging findings are most commonly of atypical or organizing pneumonia, often with a bilateral, peripheral, and basal predominant distribution. No effective treatment or vaccine exists currently (March 2020).
The document discusses various types of vaccine candidates being developed for COVID-19, including inactivated vaccines, live attenuated vaccines, subunit vaccines, virus-like particles, and nucleic acid vaccines. Inactivated vaccines containing the SARS-CoV-2 spike protein have shown promise in animal models by eliciting neutralizing antibodies. Live attenuated vaccines with gene deletions have also induced immune responses while reducing pathogenicity. Subunit vaccines using the spike protein or conserved epitopes could provide broad immunity. DNA and viral vector vaccines encoding spike or nucleocapsid have similarly generated antibody and T cell responses in animal studies. Overall, the document emphasizes the importance of vaccines that stimulate both antibody and T cell immunity to provide long-lasting protection against SARS-CoV
This document discusses several topics related to influenza vaccination:
1. It explains that even healthy individuals who have avoided the flu in the past are still at risk each year and should get vaccinated, as flu strains evolve over time.
2. It describes the difference between trivalent and quadrivalent flu vaccines, with quadrivalent vaccines protecting against two influenza A strains and two B strains.
3. It notes that yearly flu vaccines are needed because immunity decreases over time and flu viruses can drift, requiring reformulation of the vaccine each season to match circulating strains.
This document summarizes a symposium on COVID-19 vaccination. It provides an overview of COVID-19, statistics on cases and deaths globally and in India/Punjab. It discusses high-risk groups, signs and symptoms, vaccine development stages and approved vaccines. It also covers variants of concern, how vaccination works, reasons some may still get infected after vaccination due to factors like the Peltzman effect causing riskier behavior believing they are protected.
The document discusses the COVID-19 pandemic from various perspectives. It provides details on viruses, coronaviruses, the origins and spread of COVID-19, symptoms, testing, prevention, vaccine development, the roles of WHO and various governments. It also outlines the major economic, social, political, educational and psychological impacts of the pandemic. Solutions proposed to address the crisis include increased testing, contact tracing, lockdowns, use of protective equipment, shelter for vulnerable groups, managing panic, and developing a vaccine.
This document from the Fire Baptized Holiness Church provides information about COVID-19. It defines coronaviruses and explains that COVID-19 is a novel coronavirus first identified in Wuhan, China in December 2019. The virus spreads mainly between people within 6 feet through respiratory droplets from coughing and sneezing. Common symptoms include fever, cough and difficulty breathing. To protect oneself and others, frequent handwashing, social distancing and disinfecting surfaces are recommended. Those at higher risk include older adults, healthcare workers and those with chronic conditions. While there is no specific treatment, supportive care is provided to relieve symptoms.
This document discusses the emergence and progression of SARS-CoV-2 variants since late 2019. It notes that the virus has mutated numerous times, sometimes altering its transmissibility, severity of disease, or impact on vaccines and treatments. Key variants discussed include Delta and Omicron. The document provides definitions for related terms like mutation, variant, and strain. It also examines specific Omicron subvariants like BA.4, BA.5, and BF.7, exploring their symptoms and impact. Throughout, it emphasizes the importance of continued infection control measures.
The document summarizes information about COVID-19. It began in Wuhan, China in December 2019, when several cases of an unknown pneumonia were reported. Officials later identified it as a new coronavirus called SARS-CoV-2. It spreads mainly through respiratory droplets when an infected person coughs or sneezes. Common symptoms include fever, cough, and shortness of breath. While 80% of cases are mild, it can cause severe pneumonia and death in some cases, especially among the elderly and those with pre-existing conditions. China has faced over 82,000 cases but has recovered most patients, while the virus has since spread globally.
The document contains information about vaccination rates in adolescents from 2006-2008. It shows that rates of HPV vaccination and meningitis vaccination increased over this period but rates of whooping cough and tetanus vaccination were still below the Healthy People 2010 goal of 80% in 2008. Free and low-cost vaccines are available through programs like the Vaccines for Children program.
Cheryl Davis PowerPoint Presentation.pptxWeldonFultz1
This document provides information from a workshop on COVID-19 vaccines and testing. It defines key terms like virus, antigen, antibody, and vaccine. It summarizes data from clinical trials of Moderna, Pfizer and Johnson & Johnson vaccines. It illustrates how mRNA and viral vector vaccines work. It discusses PCR testing, results, and cycle threshold values. It also addresses common myths about COVID-19 vaccines.
Coronaviruses are a group of related viruses that cause diseases in mammals and birds. In humans, coronaviruses cause respiratory tract infections that can be mild, such as some cases of the common cold, and others that can be lethal, such as SARS, MERS, and COVID-19. Symptoms in other species vary: in chickens, they cause an upper respiratory tract disease, while in cows and pigs they cause diarrhea. There are yet to be vaccines or antiviral drugs to prevent or treat human coronavirus infections.
detailed information about COVID_19 and Corona Viruses how it would be transmitted and all the preventive measures
information about the vaccine of corona virus
This document summarizes information about different COVID-19 vaccines. It discusses the mechanism of action, efficacy, dosing schedule, storage requirements, and common side effects of several major vaccines, including Covishield, Covaxin, Pfizer/BioNTech, Moderna, Sinovac, Sinopharm, Johnson & Johnson, Sputnik V and Novavax. The document also briefly outlines different vaccine production approaches such as viral vector vaccines, mRNA vaccines, inactivated virus vaccines, and virus-like particle vaccines.
Webinar Series on COVID-19 vaccine: Jointly organized by Malaysian Society of Infection Control and Infectious Diseases (MyICID) & Institute for Clinical Research (ICR), NIH
Speaker: Dr.Benedict Sim Lim Heng is a Consultant Infectious Disease Physician at the Sungai Buloh Hospital, Ministry of Health Malaysia.
The document provides information about Coronavirus (COVID-19). It describes how COVID-19 is caused by SARS-CoV-2 virus and spreads mainly through respiratory droplets from infected individuals. Common symptoms include fever, cough and shortness of breath. While most cases are mild, it can progress to pneumonia and multi-organ failure in some cases. The mortality rate is around 2%. Currently there is no vaccine, though some antiviral medications are being tested. Prevention relies on hand washing and hygiene measures.
Zika virus is spread by daytime-active Aedes mosquitoes and often causes mild or no symptoms. It was isolated in Uganda in 1947 and has recently spread to areas in the Americas. The virus is associated with microcephaly in fetuses when the mother is infected during pregnancy and Guillain-Barré syndrome in adults. While medications and vaccines are currently unavailable, health organizations recommend precautions for pregnant women such as postponing travel to affected areas.
The document discusses adult immunization strategies in India. It notes there is a lack of consensus on optimal adult immunization strategies in developing countries like India due to a lack of reliable epidemiological data, efficacy and safety data of vaccination strategies, and data on monitoring immunization adequacy. The document provides guidance on recommended vaccines for different adult groups and schedules for vaccines including tetanus, diphtheria, pertussis, hepatitis A, hepatitis B, HPV, influenza, measles, mumps, rubella, varicella, herpes zoster and pneumococcal vaccines.
Chikungunya is a viral disease transmitted by infected mosquitoes that causes fever and severe joint pain. It is caused by the chikungunya virus which is spread between humans by Aedes albopictus and Aedes aegypti mosquitoes. Large outbreaks have occurred in parts of Africa, India, and Southeast Asia. Currently, there is no vaccine available and treatment focuses on relieving symptoms.
COVID-19 (coronavirus disease 2019) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019 novel coronavirus (2019-nCoV), a strain of coronavirus. The first cases were seen in Wuhan, China in December 2019 before spreading globally. The current outbreak was recognized as a pandemic on 11 March 2020.
The non-specific imaging findings are most commonly of atypical or organizing pneumonia, often with a bilateral, peripheral, and basal predominant distribution. No effective treatment or vaccine exists currently (March 2020).
The document discusses various types of vaccine candidates being developed for COVID-19, including inactivated vaccines, live attenuated vaccines, subunit vaccines, virus-like particles, and nucleic acid vaccines. Inactivated vaccines containing the SARS-CoV-2 spike protein have shown promise in animal models by eliciting neutralizing antibodies. Live attenuated vaccines with gene deletions have also induced immune responses while reducing pathogenicity. Subunit vaccines using the spike protein or conserved epitopes could provide broad immunity. DNA and viral vector vaccines encoding spike or nucleocapsid have similarly generated antibody and T cell responses in animal studies. Overall, the document emphasizes the importance of vaccines that stimulate both antibody and T cell immunity to provide long-lasting protection against SARS-CoV
This document discusses several topics related to influenza vaccination:
1. It explains that even healthy individuals who have avoided the flu in the past are still at risk each year and should get vaccinated, as flu strains evolve over time.
2. It describes the difference between trivalent and quadrivalent flu vaccines, with quadrivalent vaccines protecting against two influenza A strains and two B strains.
3. It notes that yearly flu vaccines are needed because immunity decreases over time and flu viruses can drift, requiring reformulation of the vaccine each season to match circulating strains.
This document summarizes a symposium on COVID-19 vaccination. It provides an overview of COVID-19, statistics on cases and deaths globally and in India/Punjab. It discusses high-risk groups, signs and symptoms, vaccine development stages and approved vaccines. It also covers variants of concern, how vaccination works, reasons some may still get infected after vaccination due to factors like the Peltzman effect causing riskier behavior believing they are protected.
The document discusses the COVID-19 pandemic from various perspectives. It provides details on viruses, coronaviruses, the origins and spread of COVID-19, symptoms, testing, prevention, vaccine development, the roles of WHO and various governments. It also outlines the major economic, social, political, educational and psychological impacts of the pandemic. Solutions proposed to address the crisis include increased testing, contact tracing, lockdowns, use of protective equipment, shelter for vulnerable groups, managing panic, and developing a vaccine.
This document from the Fire Baptized Holiness Church provides information about COVID-19. It defines coronaviruses and explains that COVID-19 is a novel coronavirus first identified in Wuhan, China in December 2019. The virus spreads mainly between people within 6 feet through respiratory droplets from coughing and sneezing. Common symptoms include fever, cough and difficulty breathing. To protect oneself and others, frequent handwashing, social distancing and disinfecting surfaces are recommended. Those at higher risk include older adults, healthcare workers and those with chronic conditions. While there is no specific treatment, supportive care is provided to relieve symptoms.
This document discusses the emergence and progression of SARS-CoV-2 variants since late 2019. It notes that the virus has mutated numerous times, sometimes altering its transmissibility, severity of disease, or impact on vaccines and treatments. Key variants discussed include Delta and Omicron. The document provides definitions for related terms like mutation, variant, and strain. It also examines specific Omicron subvariants like BA.4, BA.5, and BF.7, exploring their symptoms and impact. Throughout, it emphasizes the importance of continued infection control measures.
The document summarizes information about COVID-19. It began in Wuhan, China in December 2019, when several cases of an unknown pneumonia were reported. Officials later identified it as a new coronavirus called SARS-CoV-2. It spreads mainly through respiratory droplets when an infected person coughs or sneezes. Common symptoms include fever, cough, and shortness of breath. While 80% of cases are mild, it can cause severe pneumonia and death in some cases, especially among the elderly and those with pre-existing conditions. China has faced over 82,000 cases but has recovered most patients, while the virus has since spread globally.
The document contains information about vaccination rates in adolescents from 2006-2008. It shows that rates of HPV vaccination and meningitis vaccination increased over this period but rates of whooping cough and tetanus vaccination were still below the Healthy People 2010 goal of 80% in 2008. Free and low-cost vaccines are available through programs like the Vaccines for Children program.
Cheryl Davis PowerPoint Presentation.pptxWeldonFultz1
This document provides information from a workshop on COVID-19 vaccines and testing. It defines key terms like virus, antigen, antibody, and vaccine. It summarizes data from clinical trials of Moderna, Pfizer and Johnson & Johnson vaccines. It illustrates how mRNA and viral vector vaccines work. It discusses PCR testing, results, and cycle threshold values. It also addresses common myths about COVID-19 vaccines.
February 2010 Selected Zoonotic Diseases Conference Callgoa4
The document summarizes a conference call about dengue and zoonotic diseases. It discusses an update on dengue infections in the United States, including outbreaks in Texas, Hawaii and Florida. It also mentions a multistate outbreak of Salmonella infections linked to contact with aquatic frogs and recommendations provided to the public.
February 2010 Selected Zoonotic Diseases Conference Callgoa4
The document summarizes a conference call about dengue and zoonotic diseases. It discusses an update on dengue infections in the United States, including outbreaks in Texas, Hawaii and Florida. It also mentions a multistate outbreak of Salmonella infections linked to contact with aquatic frogs and recommendations provided to the public.
Latest update on cervical cancer & hpv vaccine 2013Lifecare Centre
Cervical cancer is a major cause of cancer deaths among women globally, with over 270,000 deaths per year. India has a high burden with over 100,000 new cases annually. Human papillomavirus (HPV) infection is the primary cause, with HPV types 16 and 18 causing over 70% of cervical cancers. Two HPV vaccines, a bivalent and quadrivalent vaccine, provide protection against HPV 16 and 18 and have demonstrated efficacy of over 90% in clinical trials. Ongoing monitoring in Nordic countries has found the quadrivalent vaccine continues to provide protection against HPV 16/18 infection for up to 9 years. Guidelines recommend routine HPV vaccination for girls and boys at age 11-12 to be
This document provides an overview of recent advances in HIV/AIDS treatment. It discusses how combination antiretroviral therapy pills have simplified treatment regimens. New drug classes such as entry inhibitors and integrase inhibitors have been developed that target different parts of the viral lifecycle. Studies have also shown benefits of starting antiretroviral treatment earlier, even before symptoms develop. Vaccine research continues in an effort to develop a preventive vaccine, with some studies showing a limited level of effectiveness.
The document discusses guidelines for diagnosing and treating high blood pressure from the National High Blood Pressure Education Program Coordinating Committee. It notes that systolic blood pressure is more important than diastolic pressure for those over 50 years old. It also discusses "prehypertension" between 120-139/80-89 mm Hg and treatment thresholds. The JNC 7 guidelines were issued in 1997 while the JNC 8 guidelines from 2013 include treatment algorithms and comparisons to JNC 7.
The document discusses guidelines for diagnosing and treating high blood pressure from the National High Blood Pressure Education Program Coordinating Committee. It notes that systolic blood pressure is more important than diastolic pressure for those over 50 years old. It also discusses "prehypertension" between 120-139/80-89 mm Hg and treatment thresholds. The JNC 7 guidelines were issued in 1997 while JNC 8 included treatment algorithms and differences from JNC 7.
This document provides an overview and updates on various adult vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). It discusses vaccines for influenza, pneumococcal disease, herpes zoster, Tdap, HPV, meningococcal disease, hepatitis A, and varicella. For each vaccine, it outlines the populations recommended to receive it, dosing schedules, and special considerations for immunocompromised individuals. The presentation emphasizes the importance of adult vaccinations in preventing disease and highlights changes to recommendations for the 2013-2014 season.
This document discusses several priorities related to perinatal, paediatric, and adolescent HIV. Priority 1 is early diagnosis of infant infection through tests like HIV DNA and RNA that can detect infection before antibodies are present. Priority 2 is ensuring appropriate paediatric HIV treatment formulations that are palatable, easy to administer, and stable for storage and transport. Priority 3 is obtaining long-term outcome data on rates of HIV transmission through breastfeeding while the mother is on combination antiretroviral therapy (cART). The document also discusses challenges in adolescent HIV including mental health issues, risk behaviors, and loss to follow up during transition from paediatric to adult care.
This document summarizes potential dangers of COVID-19 vaccines for children aged 12-18 based on adverse event reports. It notes that:
1) Reported adverse events following vaccination are atypically high, with over 250,000 reports including 8,500 reports for children aged 12-18, of which 17% experienced cardiovascular issues.
2) The vaccines are likely causing these adverse events as over 80% of cardiovascular, neurological, and immunological issues were reported within 1 day of vaccination.
3) The vaccines may disrupt the renin-angiotensin-aldosterone system, which regulates blood pressure and electrolytes, as the spike protein binds strongly to ACE2, a key enzyme in
This document discusses pertussis (whooping cough) and outlines the following key points:
1. Pertussis is highly communicable respiratory infection caused by Bordetella pertussis that can cause severe illness, especially in infants.
2. The epidemiology of pertussis has changed with increasing cases in adolescents and adults as immunity wanes, putting vulnerable infants at risk of exposure.
3. Strategies to prevent pertussis include adolescent and adult booster vaccinations to reduce transmission to infants who are too young to be fully protected by vaccination.
Adult vaccination-turkey-ageing- need of pneumoccocal vaccinationkaushikawebworld
This document discusses adult and elderly vaccination practices in Turkey. It provides background on the history and impact of vaccination, describing how vaccination has controlled 12 major infectious diseases. It then discusses recommendations and rates for adult vaccination in Turkey, noting the lack of coverage targets for adults. Barriers to adult vaccination are described, along with recent efforts in Turkey to improve vaccination rates through new guidelines and reimbursement policies. Overall vaccination rates in Turkey remain below targets.
Comparison of immunity against canine distemper, adenovirus and parvovirus af...Biogal
This study aimed at comparing the immunity of two multivalent vaccines in adult dogs in the city of Uberlândia, Minas Gerais state, Brazil.
VacciCheck was used in the study in order to determine the immunity levels of the dogs.
PERTUSSIS PROTECTION - CURRENT SCHEDULES IN EUROPEWAidid
Slide set by Professor Susanna Esposito, president WAidid, presented at the 3rd ESCMID Conference on Vaccines, held in Lisbon (Portugal), 6- 8 March 2015. Learn more: http://goo.gl/8GUwwL
AN OPPORTUNITY FOR HPV VACCINATION , Dr. Sharda Jain Lifecare Centre Lifecare Centre
This document discusses strategies for cervical cancer prevention in India through HPV vaccination. It notes that cervical cancer is almost entirely preventable but prevention efforts in India have been inadequate. HPV vaccination provides strong protection, especially if received before sexual debut. However, vaccination rates in India are very low. The document argues that the postpartum period provides an opportunity for catch-up HPV vaccination that can improve coverage. Several studies show high HPV prevalence in postpartum women, demonstrating the potential benefit. Other evidence suggests postpartum women are receptive to vaccination and compliance with the 3 dose schedule can be high with proper counseling. The document advocates that healthcare providers should recommend HPV vaccination to women in the postpartum period to help control cervical cancer in India
The importance of pertussis booster vaccine doses throughout life - Slideset ...WAidid
Pertussis is still a worldwide problem: every year there are almost 20-50 million cases and 300.000 deaths.
The incidence is increasing especially between adults and adolescents, with consequences on infants. For this reason, the increasing of a vaccination strategy for adolescent and adult is needed...
To learn more, please visit www.waidid.org.
The British Islamic Medical Association recommends the COVID-19 Vaccine AstraZeneca for eligible individuals in the Muslim community for protection against COVID-19 when used in accordance with regulatory approval. They note efficacy was shown to be 70.42% with mostly mild adverse reactions reported. While vaccines are now available, vigilance with preventive measures like masks and distancing remain important given continued high transmission rates disproportionately impacting ethnic minorities.
This document discusses rotavirus prevention and control. It begins with an introduction stating that rotavirus is the leading cause of severe diarrhea in children under 5 globally, resulting in over 500,000 child deaths annually. The majority of these deaths occur in low-income countries.
It then covers the epidemiology and disease burden, describing rotavirus as the top cause of death in children under 5 worldwide. Clinical presentation is discussed, outlining the typical timeline and symptoms of rotavirus infection.
Prevention and control methods are summarized as infection control practices and vaccination. Two oral rotavirus vaccines currently available are described and their efficacy and safety are discussed. WHO recommendations for rotavirus vaccination through national immunization
10 Benefits an EPCR Software should Bring to EMS Organizations Traumasoft LLC
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
How to Control Your Asthma Tips by gokuldas hospital.Gokuldas Hospital
Respiratory issues like asthma are the most sensitive issue that is affecting millions worldwide. It hampers the daily activities leaving the body tired and breathless.
The key to a good grip on asthma is proper knowledge and management strategies. Understanding the patient-specific symptoms and carving out an effective treatment likewise is the best way to keep asthma under control.
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
5. CORONAVIRUS
Coronaviruses are a group of related RNA viruses that cause diseases
in mammals and birds.
In humans and birds, they cause respiratory tract infections that can
range from mild to lethal.
Mild illnesses in humans include some cases of the common cold
(which is also caused by other viruses, predominantly rhinoviruses),
while more lethal varieties can cause SARS, MERS, and COVID-19.
In cows and pigs they cause diarrhea, while in mice they cause
hepatitis and encephalomyelitis.
The name “coronavirus” is derived from Latin corona, meaning
“crown” or “wreath”
6. The name was coined by June Almeida and David Tyrrell who first
observed and studied human coronaviruses.
Bats and birds, as warm-blooded flying vertebrates, are an ideal
natural reservoir for the coronavirus gene pool (with bats the
reservoir for alphacoronaviruses and betacoronavirus – and birds the
reservoir for gammacoronaviruses and deltacoronaviruses).
Coronavirus disease 2019 (COVID-19):
In December 2019, a pneumonia outbreak was reported in Wuhan,
China.
On 31 December 2019, the outbreak was traced to a novel strain of
coronavirus, which was given the interim name 2019-nCoV by the
World Health Organization (WHO), later renamed SARS-CoV-2 by the
International Committee on Taxonomy of Viruses.
As of 9 April 2021, there have been at least 2,904,554 confirmed
deaths and more than 134,038,180 confirmed cases in the COVID-19
pandemic.
7. VARIANTS OF COVID19
B.1.1.7: This variant was first identified in the US in December 2020.
It was initially detected in the UK.
B.1.351: This variant was first identified in the US at the end of
January 2021. It was initially detected in South Africa in December
2020.
P.1: This variant was first detected in the US in January 2021. P.1 was
initially identified in travelers from Brazil, who were tested during
routine screening at an airport in Japan, in early January.
B.1.427 and B.1.429: These two variants were first identified in
California in February 2021 and were classified as VOCs in March
2021.
10. GENERAL INFORMATION ABOUT PFIZER
VACCINE
Name: BNT162b2
Manufacturer: Pfizer Inc and BioNTech
Manufacturer country: United States of America (USA)
Type of Vaccine: mRNA
Number of shots: 2shots, 21 days apart
How given: Shot in the muscle of upper arm
Based on evidence from clinical trials, Pfizer vaccine was 97%
effective at preventing laboratory confirmed COVID19 illness in
people without evidence of previous infection.
11. Possible Side
Effects
In arm where you got the shots
1. Pain
2. Redness
3. Swelling
Rest of the body
1. Tiredness
2. Headache
3. Muscle pain
4. Chill
5. Fever
6. Nausae
Who Should Get Vaccinated
The Pfizer-BioNTech vaccine is
recommended for people aged 16
years and older.
Who Should NOT Get Vaccinated
If you have had a severe allergic
reaction (anaphylaxis) or an
immediate allergic reaction.
Storage and Handling Overview
Store vaccine in an ultra-cold
freezer, freezer, thermal shipping
container, or refrigerator.
12. CLINICAL TRIAL DEMOGRAPHIC INFORMATION
Clinical trials for the Pfizer-BioNTech vaccine included people from
the following racial and ethnic, age, and sex categories:
1. 81.9% White
2. 9.8% African American
3. 4.4% Asian
4. <3% other races/ethnicities
5. <1% Native Hawaiian or Other PacificIslander
6. <1% American Indian or Alaska Native
Ethnicity
1. 2% Not Hispanic or Latino
2. 2% Hispanic of Latino
3. <1% Not Reported
13. Age and sex breakdown:
1. 50.6% male
2. 49.4% female
3. 21.4% 65 years and older
Age
1. 9% 16 to 55 years
2. 8% 55 years and older
3. 4% 65 years and older
4. 3% 75 years and older
The most frequent underlying medical conditions were obesity
(35.1%), diabetes (8.4%), and pulmonary disease (7.8%).
15. GENERAL INFORMATION ABOUT
MODERNA VACCINE
Name: mRNA – 1273
Manufacturer: ModernaTX Inc
Manufacturer country: United States of America (USA)
Type of Vaccine: mRNA
Number of shots: 2shots, 28 days apart
How given: Shot in the muscle of upper arm
Based on evidence from clinical trials, Moderna vaccine was 94.1%
effective at preventing laboratory confirmed COVID19 illness in
people without evidence of previous infection.
16. Possible Side Effects
In arm where you got the shots
1. Pain
2. Redness
3. Swelling
Rest of the body
1. Tiredness
2. Headache
3. Muscle pain
4. Chill
5. Fever
6. Nausae
Who Should Get Vaccinated
The Moderna vaccine is
recommended for people aged 18
years and older.
Who Should NOT Get Vaccinated
If you have had a severe allergic
reaction (anaphylaxis) or an
immediate allergic reaction
Storage and Handling Overview
Store vaccine in a freezer or
refrigerator.
17. CLINICAL TRIAL DEMOGRAPHIC INFORMATION
Clinical trials for the Moderna vaccine included people from the
following racial and ethnic, age, and sex categories:
1. 79.4% White
2. 9.7% African American
3. 4.7% Asian
4. <3% other races/ethnicities
5. <1% American Indian or Alaska Native
6. <1% Native Hawaiian or Other Pacific Islander
Ethnicity:
1. 79.1% Not Hispanic or Latino
2. 20.0% Hispanic or Latino
3. 0.9% Unknown
18. Sex breakdown:
1. 52.6% male
2. 47.4% female
Age breakdown:
1. 74.7% 18 – 64 years
2. 25.3% 65 years and older
Most people who participated in the trials (82%) were considered to
have an occupational risk of exposure, with 25.4% of them being
healthcare workers.
Among people who participated in the clinical trials, 22.3% had at
least one high-risk condition, which included lung disease, heart
disease, obesity, diabetes, liver disease, or HIV infection. Four
percent (4%) of participants had two or more high-risk conditions.
20. GENERAL INFORMATION ABOUT
JOHNSON AND JOHNSON’S JANSSEN
VACCINE
Name: JNJ – 78436735
Manufacturer: Janssen Pharmaceutical company of Johnson and
Johnson
Manufacturer country: Leiden, Netherlands and United States of
America (USA)
Type of Vaccine: Viral vector
Number of shots: 1 shot
How given: Shot in the muscle of upper arm
Based on evidence from clinical trials, Janssen vaccine was 66.3%
effective at preventing laboratory confirmed COVID19 illness in
people without evidence of previous infection.
21. Possible Side Effects
In arm where you got the shots
1. Pain
2. Redness
3. Swelling
Rest of the body
1. Tiredness
2. Headache
3. Muscle pain
4. Chill
5. Fever
6. Nausae
Who Should Get Vaccinated
The J&J/Janssen vaccine is recommended
for people aged 18 years and older.
Who Should NOT Get Vaccinated
If you have had a severe allergic reaction
(anaphylaxis) or an immediate allergic
reaction.
Storage and Handling Overview
Store vaccine in a freezer or refrigerator.
22. CLINICAL TRIAL DEMOGRAPHIC INFORMATION
Clinical trials for the J&J/Janssen vaccine included people from the
following racial and ethnic categories:
1. 62.1% White
2. 17.2% Black or African American
3. 8.3% American Indian or Alaska Native
4. 5.4% Multiple races
5. 3.5% Asian
6. 0.3% Native Hawaiian or other Pacific Islander
Ethnicity:
1. 45.1% Hispanic or Latino
2. 52.4% Not Hispanic or Latino
3. 2.5% Unknown
23. Sex breakdown:
1. 55.5% Male
2. 44.5% Female
3. <0.1% Undifferentiated or unknown sex
Age breakdown:
1. 66.5% 18–59 years
2. 33.5% 60 years and older
3. 19.6% 65 years and older
4. 3.5% 75 years and older
25. GENERAL INFORMATION ABOUT
COVAXIN VACCINE
Name: BBV 154
Manufacturer: Bharat Biotech
Manufacturer country: India
Type of Vaccine: Inactivated
Number of shots:2 shots, 28 days apart
How given: Shot in the muscle of upper arm
Based on evidence from clinical trials, Covaxin vaccine was 81%
effective at preventing laboratory confirmed COVID19 illness in
people without evidence of previous infection.
26. Possible Side Effects
In arm where you got the shots
1. Pain
2. Redness
3. Swelling
Rest of the body
1. Tiredness
2. Headache
3. Muscle pain
4. Chill
5. Fever
6. Nausae
Who Should Get Vaccinated
The Bharat Biotech vaccine is recommended for
people aged 12 years and older.
Who Should NOT Get Vaccinated
If you have had a severe allergic reaction
(anaphylaxis) or an immediate allergic reaction.
Storage and Handling Overview
It is a vaccine with no sub-zero storage, no
reconstitution requirement, and ready to use
liquid presentation in multi-dose vials, stable at
2-8oC.
27. A total of 375 subjects have been enrolled in the Phase 1 study and
generated excellent safety data without any reactogenicity.
Vaccine-induced neutralizing antibody titers were observed with
two divergent SARS-CoV-2 strains.
Percentage of all the side-effects combined was only 15% in vaccine
recipients.
In Phase 2 study, 380 participants of 12-65 years were enrolled.
COVAXIN led to tolerable safety outcomes and enhanced humoral
and cell-mediated immune responses.
A total of 25,800 subjects have been enrolled and randomized in a
1:1 ratio to receive the vaccine and control in a Event-Driven,
randomized, double-blind, placebo-controlled, multicentre phase 3
study.
28. COVAXIN effective against UK variant
strain and Global Acceptance of
COVAXIN:
Analysis from the National Institute of Virology indicates that
vaccine-induced antibodies can neutralize the UK variant strains and
other heterologous strains.
Bharat biotech has been approached by several countries across the
world for the procurement of COVAXIN.
Clinical trials in other countries to commence soon.
29. Supplies from government to government in the following countries
to take place:
1. Mongolia
2. Myanmar
3. Sri Lanka
4. Philippines
5. Bahrain
6. Oman
7. Maldives
8. Mauritius
9. Bangladesh
10. Nepal
31. GENERAL INFORMATION ABOUT
COVISHIELD VACCINE
Name: ChAdOx1 or AZD1222
Manufacturer: Serum Institute of India, AstraZeneca and Oxford
University
Manufacturer country: India, UK and British- Swedish.
Type of Vaccine: Non-replicating Viral vector
Number of shots:2 shots, 48 days apart
How given: Shot in the muscle of upper arm
Based on evidence from clinical trials, Covishield vaccine was 95%
effective at preventing laboratory confirmed COVID19 illness in
people without evidence of previous infection.
32. Possible Side Effects
In arm where you got the shots
1. Pain
2. Redness
3. Swelling
Rest of the body
1. Tiredness
2. Headache
3. Muscle pain
4. Chill
5. Fever
6. Nausae
Who Should Get Vaccinated
The Covishield vaccine is recommended
for people aged 18 years and older.
Who Should NOT Get Vaccinated
If you have had a severe allergic reaction
(anaphylaxis) or an immediate allergic
reaction.
Storage and Handling Overview
It is a vaccine with no sub-zero storage,
no reconstitution requirement, and ready
to use liquid presentation in multi-dose
vials, stable at 2-8oC.
34. GENERAL INFORMATION ABOUT
COVISHIELD VACCINE
Name: Gam – COVID – Vac
Manufacturer: Gamaleya Research Institute of Epidemiology and
Microbiology
Manufacturer country: Russia.
Type of Vaccine: Viral vector
Number of shots:2 shots, 21 days apart
How given: Shot in the muscle of upper arm
Based on evidence from clinical trials, Sputnik V vaccine was 91.6%
effective at preventing laboratory confirmed COVID19 illness in
people without evidence of previous infection.
35. Possible Side Effects
In arm where you got the shots
1. Pain
2. Redness
3. Swelling
Rest of the body
1. Tiredness
2. Headache
3. Muscle pain
4. Chill
5. Fever
6. Nausae
Who Should Get Vaccinated
The Sputnik V vaccine is recommended for
people aged 18 years and older.
Who Should NOT Get Vaccinated
If you have had a severe allergic reaction
(anaphylaxis) or an immediate allergic reaction.
Storage and Handling Overview
Storage temperature is above freezing, 2–8 °C
or 36–46 °F, at the common home-refrigerator
temperature. The freeze-dried powder must be
reconstituted with water for before use.
36. OTHER VACCINES
The non – mentioned Vaccines are as follow:
1. BBIBP – CorV: Manufactured by Sinopharm, China with a
effectiveness of 86%.
2. ZyCoV – D: Manufactured by Zydus Candela, India, is under third
phase of clinical trials.
3. CoviVac: Manufactured by Russian Institute of Science, Russia, is
under third phase of clinical trials.
4. WIBP – CorV: Manufactured by Sinopharm, China with a
effectiveness of 72.51%.